634.7500 -15.15 (-2.33%)
NSE May 02, 2025 15:31 PM
Volume: 331.5K
 

634.75
-2.33%
Axis Direct
Strides reported Q4'17 EBITDA of Rs 1.56bn, 28% below our expectations, hit by challenging environment across key markets. EBITDA including other income was Rs 2.1 bn, which is ~95% of H2'17 EBITDA guidance.
Strides Pharma Science Ltd. is trading below all available SMAs
More from Strides Pharma Science Ltd.
Recommended